We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/... Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers. Show more
Plan to complete NDA submission with the mature RAMP 201 dataset, anticipated to include 12 months of follow-up, in the second half of 2024 Plan to present the mature dataset from RAMP 201 at a...
83% (5/6) of patients achieved a confirmed partial response in cohort 1, the most mature dose level; one dose-limiting toxicity was observed, however, the dose level was subsequently cleared...
Plan to announce topline RAMP 201 data with the start of planned rolling NDA submission for avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer in Q2 2024 FDA...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a...
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncologyβs international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -7.6 | -65.2920962199 | 11.64 | 12.45 | 4 | 5077298 | 4.39722408 | CS |
4 | -5.63 | -58.221302999 | 9.67 | 13.52 | 4 | 1173829 | 5.05879637 | CS |
12 | -8.39 | -67.4979887369 | 12.43 | 13.52 | 4 | 468212 | 6.17468785 | CS |
26 | -2.46 | -37.8461538462 | 6.5 | 14.22 | 4 | 283058 | 7.23406378 | CS |
52 | -8.56 | -67.9365079365 | 12.6 | 15.18 | 4 | 355177 | 9.589798 | CS |
156 | -44.08 | -91.604322527 | 48.12 | 59.22 | 3.474 | 1353824 | 20.34693104 | CS |
260 | -11.92 | -74.686716792 | 15.96 | 59.22 | 3.474 | 2131001 | 22.23283027 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions